广生堂：乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验首例受试者成功入组

Group 1 - The core point of the article is that Guangshentang (300436) announced the successful enrollment of the first subject in the Phase III clinical trial of its innovative hepatitis B treatment drug, GST-HG141, on July 25, 2025 [1] - The Phase III clinical trial is a randomized, double-blind, placebo-controlled, multi-center study aimed at evaluating GST-HG141 for patients with chronic hepatitis B (CHB) who have poor antiviral response [1] - The trial has received ethical approval from the ethics committees of the leading institutions, including Shulan (Hangzhou) Hospital and Peking University First Hospital, and patient enrollment has commenced [1]